Mirum Pharmaceuticals Inc.

5 trials 2 recruiting Commercial sponsor

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

2 Recruiting

2 Completed trials

7 Countries active

4 Unique IMPs

100% Results reported

Phase III

Phase II

Phase IV

Phase III: 1 Phase II: 3 Phase IV: 1

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Alagille syndrome 1 Progressive familial intrahepatic cholestasis 1 Primary biliary cholangitis 1 Fragile X syndrome 1

Top IMPs

VOLIXIBAT 2 MARALIXIBAT 1 MARALIXIBAT CHLORIDE 1 MRM-3379 1

All trials

5 total

Study of MRM-3379 in Male Participants with Fragile X Syndrome Pending

2025-523738-21-00 Phase II 1 country MRM-3379
Long Term Study of Livmarli Recruiting

2024-516804-40-00 Phase IV 6 countries MARALIXIBAT
A study to evaluate efficacy and safety of an investigational drug named volixibat in patients with itching caused by primary biliary cholan… Recruiting

2023-504660-41-00 Phase II 6 countries VOLIXIBAT
Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Participants… Ended

2024-511287-85-00 Phase III 5 countries MARALIXIBAT CHLORIDE
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cho… Ended

2023-505764-11-00 Phase II 6 countries VOLIXIBAT

Showing 1–5 of 5 trials

← All sponsors A–Z